patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_555527 | REC_0013401 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.5 | 72 | female | 1 | 46 | 6.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.3 | false | MSS | 2026-03-15T05:36:00.377161+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833778 | REC_0013402 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6 | 58 | male | 0 | 36 | 6.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.2 | false | MSS | 2026-03-15T05:36:00.377483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354952 | REC_0013403 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 8.1 | 73 | female | 0 | 44 | 5.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 5.4 | true | MSS | 2026-03-15T05:36:00.377786+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218570 | REC_0013404 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 10.8 | 74 | female | 2 | 10 | 4.2 | 1 | osimertinib 80 mg daily | 21.1 | false | MSS | 2026-03-15T05:36:00.378262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119975 | REC_0013405 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 3.1 | 63 | female | 1 | 18 | 4.5 | 6 | pembrolizumab 200 mg q3w | 10.5 | false | MSS | 2026-03-15T05:36:00.378620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764749 | REC_0013406 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 16.5 | 71 | male | 2 | 6 | 5.3 | 6 | osimertinib 80 mg daily | 8.2 | true | MSS | 2026-03-15T05:36:00.378956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792436 | REC_0013407 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 14.9 | 69 | female | 0 | 20 | 4.8 | 5 | osimertinib 80 mg daily | 8.9 | false | MSS | 2026-03-15T05:36:00.379292+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_410564 | REC_0013408 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 6.3 | 66 | female | 1 | 21 | 6.3 | 5 | osimertinib 80 mg daily | 15.3 | false | MSS | 2026-03-15T05:36:00.379624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250339 | REC_0013409 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 13 | 12.8 | 75 | female | 2 | 17 | 4 | 7 | alectinib 600 mg BID | 10.5 | true | MSS | 2026-03-15T05:36:00.379933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210678 | REC_0013410 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 7.6 | 70 | female | 1 | 18 | 7.3 | 1 | osimertinib 80 mg daily | 14.3 | true | MSS | 2026-03-15T05:36:00.380390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823752 | REC_0013411 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 12.8 | 66 | female | 1 | 6 | 5.5 | 7 | osimertinib 80 mg daily | 5.4 | true | MSI-H | 2026-03-15T05:36:00.380754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546296 | REC_0013412 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 14.1 | 52 | male | 0 | 15 | 4.7 | 7 | osimertinib 80 mg daily | 9.2 | true | MSI-H | 2026-03-15T05:36:00.381097+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547405 | REC_0013413 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 20 | 14.9 | 51 | male | 0 | 29 | 4 | 0 | osimertinib 80 mg daily | 34.4 | false | MSS | 2026-03-15T05:36:00.381414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244068 | REC_0013414 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 20 | 61 | male | 0 | 11 | 3.2 | 7 | entrectinib 600 mg daily | 7.5 | true | MSI-H | 2026-03-15T05:36:00.381737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774776 | REC_0013415 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 14.2 | 72 | female | 2 | 10 | 5.4 | 2 | osimertinib 80 mg daily | 26.8 | false | MSI-H | 2026-03-15T05:36:00.382114+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872439 | REC_0013416 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 21 | 8.8 | 68 | female | 1 | 34 | 4 | 0 | carboplatin + paclitaxel + pembrolizumab | 22.8 | false | MSS | 2026-03-15T05:36:00.382477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459208 | REC_0013417 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 12.2 | 72 | female | 2 | 17 | 4.2 | 1 | osimertinib 80 mg daily | 20.5 | true | MSI-H | 2026-03-15T05:36:00.382977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548754 | REC_0013418 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 8 | 61 | male | 0 | 13 | 4.5 | 4 | osimertinib 80 mg daily | 12 | false | MSS | 2026-03-15T05:36:00.383382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_502110 | REC_0013419 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 16.6 | 63 | female | 1 | 21 | 6.1 | 1 | osimertinib 80 mg daily | 12.3 | false | MSS | 2026-03-15T05:36:00.383775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765907 | REC_0013420 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 17 | 63 | female | 0 | 13 | 6.2 | 2 | entrectinib 600 mg daily | 18.9 | false | MSS | 2026-03-15T05:36:00.384566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_112952 | REC_0013421 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 20.9 | 69 | female | 0 | 22 | 5.2 | 1 | sotorasib 960 mg daily | 20.8 | true | MSS | 2026-03-15T05:36:00.385037+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_954406 | REC_0013422 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 7.4 | 52 | female | 0 | 11 | 6.7 | 6 | entrectinib 600 mg daily | 9.5 | true | MSS | 2026-03-15T05:36:00.385408+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677958 | REC_0013423 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 16 | 13.8 | 67 | female | 1 | 26 | 5.5 | 0 | osimertinib 80 mg daily | 26.8 | false | MSI-H | 2026-03-15T05:36:00.385805+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459012 | REC_0013424 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 11 | 85 | male | 2 | 16 | 4 | 7 | osimertinib 80 mg daily | 8.6 | true | MSI-H | 2026-03-15T05:36:00.386202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_484351 | REC_0013425 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 16.5 | 59 | female | 0 | 15 | 4 | 8 | entrectinib 600 mg daily | 14.1 | false | MSI-H | 2026-03-15T05:36:00.386648+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_704935 | REC_0013426 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 16.3 | 89 | female | 1 | 22 | 6.8 | 1 | entrectinib 600 mg daily | 9.5 | true | MSI-H | 2026-03-15T05:36:00.387074+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_367644 | REC_0013427 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 11.3 | 63 | female | 1 | 19 | 4.5 | 2 | alectinib 600 mg BID | 19.2 | true | MSI-H | 2026-03-15T05:36:00.387470+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_924329 | REC_0013428 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 8.8 | 67 | female | 1 | 82 | 4.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.2 | true | MSS | 2026-03-15T05:36:00.387814+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_818718 | REC_0013429 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 30 | 7.1 | 64 | female | 0 | 22 | 6.2 | 2 | pembrolizumab 200 mg q3w | 21.6 | false | MSS | 2026-03-15T05:36:00.389179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_954958 | REC_0013430 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 11.4 | 62 | female | 1 | 11 | 6.2 | 2 | osimertinib 80 mg daily | 9.3 | false | MSS | 2026-03-15T05:36:00.389822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_372979 | REC_0013431 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 11.2 | 76 | female | 2 | 19 | 6.9 | 4 | osimertinib 80 mg daily | 8.4 | false | MSS | 2026-03-15T05:36:00.390230+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_822681 | REC_0013432 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 29 | 7.1 | 78 | female | 2 | 1 | 4 | 0 | osimertinib 80 mg daily | 29 | true | MSS | 2026-03-15T05:36:00.390570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201781 | REC_0013433 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 22 | 2.6 | 73 | female | 1 | 43 | 6.3 | 0 | pembrolizumab 200 mg q3w | 38.6 | true | MSS | 2026-03-15T05:36:00.390883+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752352 | REC_0013434 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 29 | 5.2 | 64 | female | 1 | 48 | 5.5 | 2 | pembrolizumab 200 mg q3w | 24.9 | true | MSS | 2026-03-15T05:36:00.391199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_477278 | REC_0013435 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 21 | 6.4 | 72 | female | 1 | 21 | 5.8 | 2 | pembrolizumab 200 mg q3w | 30.5 | true | MSS | 2026-03-15T05:36:00.391515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546213 | REC_0013436 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 7 | 55 | female | 1 | 12 | 7.5 | 1 | alectinib 600 mg BID | 23.6 | false | MSS | 2026-03-15T05:36:00.391831+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558838 | REC_0013437 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 11.4 | 73 | female | 2 | 29 | 5.9 | 6 | pembrolizumab 200 mg q3w | 12.3 | false | MSS | 2026-03-15T05:36:00.392972+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885463 | REC_0013438 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 12.8 | 64 | male | 0 | 16 | 5 | 5 | sotorasib 960 mg daily | 13.4 | true | MSI-H | 2026-03-15T05:36:00.393440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788053 | REC_0013439 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 9.3 | 55 | male | 0 | 13 | 4.2 | 2 | sotorasib 960 mg daily | 20.6 | false | MSS | 2026-03-15T05:36:00.393793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_654532 | REC_0013440 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 8.5 | 56 | male | 1 | 0 | 6.1 | 5 | osimertinib 80 mg daily | 10.2 | true | MSS | 2026-03-15T05:36:00.394107+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645395 | REC_0013441 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 10.2 | 54 | male | 0 | 10 | 5 | 6 | osimertinib 80 mg daily | 15.3 | false | MSI-H | 2026-03-15T05:36:00.394416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_733466 | REC_0013442 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.3 | 63 | male | 1 | 68 | 7.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.9 | true | MSS | 2026-03-15T05:36:00.394707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670556 | REC_0013443 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 32 | 6.7 | 73 | female | 2 | 16 | 6.2 | 7 | pembrolizumab 200 mg q3w | 13.2 | true | MSS | 2026-03-15T05:36:00.395146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_542944 | REC_0013444 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 13.9 | 67 | female | 1 | 11 | 5.8 | 8 | entrectinib 600 mg daily | 4.6 | true | MSI-H | 2026-03-15T05:36:00.395464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843388 | REC_0013445 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 14 | 7.4 | 59 | male | 0 | 19 | 5.7 | 8 | pembrolizumab 200 mg q3w | 15.8 | true | MSS | 2026-03-15T05:36:00.395756+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824578 | REC_0013446 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 16.4 | 65 | female | 1 | 13 | 5.7 | 4 | entrectinib 600 mg daily | 11.7 | true | MSS | 2026-03-15T05:36:00.396041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786702 | REC_0013447 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 14.3 | 71 | male | 0 | 22 | 7.7 | 7 | osimertinib 80 mg daily | 23.8 | true | MSS | 2026-03-15T05:36:00.396824+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855793 | REC_0013448 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 9.9 | 78 | female | 1 | 11 | 8 | 7 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:00.397176+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_229577 | REC_0013449 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 7.5 | 69 | female | 0 | 3 | 5.5 | 3 | alectinib 600 mg BID | 16.4 | true | MSS | 2026-03-15T05:36:00.397479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_863093 | REC_0013450 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 13 | 74 | male | 0 | 15 | 4.5 | 2 | entrectinib 600 mg daily | 11.2 | false | MSI-H | 2026-03-15T05:36:00.397782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577716 | REC_0013451 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 14 | 66 | female | 0 | 6 | 5.6 | 4 | sotorasib 960 mg daily | 11.2 | true | MSS | 2026-03-15T05:36:00.398126+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498954 | REC_0013452 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 16.2 | 65 | male | 0 | 13 | 3.9 | 2 | entrectinib 600 mg daily | 27.8 | false | MSI-H | 2026-03-15T05:36:00.398480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264178 | REC_0013453 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 17 | 63 | male | 0 | 13 | 6.9 | 6 | entrectinib 600 mg daily | 9.1 | false | MSS | 2026-03-15T05:36:00.398837+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173247 | REC_0013454 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 4.8 | 67 | female | 1 | 2 | 5.7 | 3 | pembrolizumab 200 mg q3w | 11.2 | false | MSS | 2026-03-15T05:36:00.399157+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488318 | REC_0013455 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 7 | 58 | female | 1 | 28 | 2.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 18 | false | MSS | 2026-03-15T05:36:00.399482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239879 | REC_0013456 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 8.5 | 69 | female | 0 | 13 | 4.4 | 8 | alectinib 600 mg BID | 14.6 | false | MSS | 2026-03-15T05:36:00.400061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136659 | REC_0013457 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 10.6 | 68 | female | 1 | 18 | 6.7 | 1 | entrectinib 600 mg daily | 20.9 | true | MSI-H | 2026-03-15T05:36:00.400556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_683975 | REC_0013458 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 6.3 | 59 | male | 1 | 12 | 3.4 | 2 | sotorasib 960 mg daily | 16.9 | false | MSS | 2026-03-15T05:36:00.400924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_530590 | REC_0013459 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 15.7 | 66 | female | 1 | 13 | 7.6 | 6 | sotorasib 960 mg daily | 14.1 | false | MSS | 2026-03-15T05:36:00.401248+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_870645 | REC_0013460 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 22 | 8.1 | 69 | female | 0 | 12 | 4.8 | 0 | osimertinib 80 mg daily | 10.5 | true | MSS | 2026-03-15T05:36:00.401548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501794 | REC_0013461 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 7.6 | 69 | female | 0 | 30 | 5.3 | 4 | sotorasib 960 mg daily | 12.6 | true | MSS | 2026-03-15T05:36:00.401844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_151562 | REC_0013462 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 14 | 63 | female | 0 | 15 | 6.3 | 7 | sotorasib 960 mg daily | 10.1 | true | MSS | 2026-03-15T05:36:00.402161+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641299 | REC_0013463 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 6.6 | 70 | female | 1 | 68 | 4.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 31.7 | false | MSS | 2026-03-15T05:36:00.402490+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306831 | REC_0013464 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 15.2 | 74 | male | 2 | 14 | 6.1 | 2 | osimertinib 80 mg daily | 13.3 | false | MSS | 2026-03-15T05:36:00.402860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507038 | REC_0013465 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 7.2 | 66 | female | 0 | 11 | 6.3 | 4 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:36:00.403206+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859546 | REC_0013466 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 14.4 | 57 | male | 0 | 19 | 5.9 | 4 | sotorasib 960 mg daily | 10.3 | false | MSS | 2026-03-15T05:36:00.403549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_268885 | REC_0013467 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 10.7 | 81 | female | 0 | 9 | 3.7 | 1 | osimertinib 80 mg daily | 7.1 | true | MSS | 2026-03-15T05:36:00.403899+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_691377 | REC_0013468 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 11.1 | 76 | male | 2 | 11 | 2.4 | 1 | alectinib 600 mg BID | 26.4 | false | MSS | 2026-03-15T05:36:00.404736+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375091 | REC_0013469 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 5.5 | 71 | female | 2 | 8 | 5.3 | 3 | osimertinib 80 mg daily | 15.4 | false | MSS | 2026-03-15T05:36:00.405303+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_950742 | REC_0013470 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 34 | 10.4 | 63 | female | 0 | 18 | 4.6 | 4 | osimertinib 80 mg daily | 15.8 | false | MSS | 2026-03-15T05:36:00.405658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_443881 | REC_0013471 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 33 | 4.6 | 63 | male | 1 | 71 | 5.7 | 1 | pembrolizumab 200 mg q3w | 20.8 | false | MSS | 2026-03-15T05:36:00.405977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634701 | REC_0013472 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 8.8 | 74 | female | 2 | 31 | 6.1 | 3 | carboplatin + paclitaxel + pembrolizumab | 14.7 | false | MSS | 2026-03-15T05:36:00.406289+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_727793 | REC_0013473 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 12.2 | 76 | male | 1 | 15 | 5.5 | 7 | alectinib 600 mg BID | 15.2 | false | MSS | 2026-03-15T05:36:00.406597+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876312 | REC_0013474 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 13.2 | 74 | female | 1 | 25 | 4.3 | 3 | osimertinib 80 mg daily | 7.4 | false | MSS | 2026-03-15T05:36:00.406891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593620 | REC_0013475 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 4.1 | 63 | female | 1 | 17 | 4.4 | 5 | alectinib 600 mg BID | 15.2 | true | MSS | 2026-03-15T05:36:00.407188+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_156798 | REC_0013476 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 11.4 | 65 | female | 1 | 13 | 6.5 | 1 | entrectinib 600 mg daily | 19.1 | false | MSS | 2026-03-15T05:36:00.407475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762753 | REC_0013477 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 8.4 | 78 | male | 1 | 46 | 5.7 | 9 | pembrolizumab 200 mg q3w | 9.3 | false | MSS | 2026-03-15T05:36:00.407758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295729 | REC_0013478 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 8.6 | 68 | male | 0 | 11 | 5.6 | 5 | sotorasib 960 mg daily | 11.7 | true | MSS | 2026-03-15T05:36:00.408064+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623158 | REC_0013479 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 21.8 | 69 | female | 0 | 18 | 6.8 | 1 | entrectinib 600 mg daily | 26.1 | true | MSI-H | 2026-03-15T05:36:00.408845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208895 | REC_0013480 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 14.1 | 70 | female | 0 | 10 | 7.2 | 5 | sotorasib 960 mg daily | 15.3 | false | MSS | 2026-03-15T05:36:00.409249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939775 | REC_0013481 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 9.5 | 78 | female | 1 | 11 | 4.9 | 6 | entrectinib 600 mg daily | 10.8 | true | MSS | 2026-03-15T05:36:00.409568+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879647 | REC_0013482 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 5.2 | 77 | female | 2 | 13 | 6 | 9 | osimertinib 80 mg daily | 6.6 | false | MSS | 2026-03-15T05:36:00.410038+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664625 | REC_0013483 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.8 | 73 | female | 3 | 20 | 4.1 | 6 | alectinib 600 mg BID | 9 | true | MSS | 2026-03-15T05:36:00.410386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387414 | REC_0013484 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 11.2 | 57 | male | 0 | 18 | 6 | 1 | osimertinib 80 mg daily | 17.1 | true | MSS | 2026-03-15T05:36:00.410701+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_526385 | REC_0013485 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 14.3 | 65 | female | 1 | 16 | 6.5 | 4 | osimertinib 80 mg daily | 14.8 | false | MSS | 2026-03-15T05:36:00.411015+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_112945 | REC_0013486 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 15 | 73 | female | 2 | 7 | 6 | 1 | sotorasib 960 mg daily | 23.7 | false | MSS | 2026-03-15T05:36:00.411310+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248788 | REC_0013487 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 16.9 | 68 | female | 0 | 18 | 6.3 | 7 | alectinib 600 mg BID | 16.1 | false | MSS | 2026-03-15T05:36:00.411611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121129 | REC_0013488 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 3.4 | 65 | male | 1 | 46 | 3.9 | 1 | pembrolizumab 200 mg q3w | 22 | false | MSS | 2026-03-15T05:36:00.411915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_338758 | REC_0013489 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 20.4 | 57 | female | 0 | 22 | 6 | 0 | sotorasib 960 mg daily | 24.5 | false | MSI-H | 2026-03-15T05:36:00.412307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402311 | REC_0013490 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 10.3 | 57 | female | 1 | 15 | 6.3 | 5 | sotorasib 960 mg daily | 10.2 | false | MSS | 2026-03-15T05:36:00.412635+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487630 | REC_0013491 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 29 | 5.9 | 65 | female | 0 | 12 | 5.9 | 1 | pembrolizumab 200 mg q3w | 18.8 | false | MSS | 2026-03-15T05:36:00.412939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621277 | REC_0013492 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 10.4 | 66 | female | 0 | 14 | 6 | 5 | osimertinib 80 mg daily | 16.3 | false | MSI-H | 2026-03-15T05:36:00.413240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377283 | REC_0013493 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 11.2 | 72 | female | 1 | 16 | 5.9 | 1 | pembrolizumab 200 mg q3w | 9.4 | true | MSI-H | 2026-03-15T05:36:00.413562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572825 | REC_0013494 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 18.7 | 58 | male | 0 | 17 | 3.5 | 3 | alectinib 600 mg BID | 11.5 | true | MSI-H | 2026-03-15T05:36:00.413872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857491 | REC_0013495 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 8.9 | 67 | female | 1 | 18 | 3.2 | 2 | alectinib 600 mg BID | 26.2 | true | MSS | 2026-03-15T05:36:00.414351+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_869101 | REC_0013496 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 12.9 | 74 | female | 2 | 12 | 7.4 | 5 | entrectinib 600 mg daily | 13 | true | MSS | 2026-03-15T05:36:00.414696+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_904250 | REC_0013497 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 9.2 | 71 | female | 2 | 20 | 7.5 | 4 | entrectinib 600 mg daily | 8.5 | false | MSS | 2026-03-15T05:36:00.415029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_447538 | REC_0013498 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 11.9 | 66 | female | 0 | 21 | 5.1 | 1 | osimertinib 80 mg daily | 23.8 | true | MSS | 2026-03-15T05:36:00.415371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294883 | REC_0013499 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 11.3 | 49 | male | 0 | 0 | 7.5 | 3 | alectinib 600 mg BID | 7.8 | false | MSS | 2026-03-15T05:36:00.415699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_601219 | REC_0013500 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 17 | 9.4 | 56 | male | 1 | 8 | 4.9 | 3 | osimertinib 80 mg daily | 28.3 | false | MSS | 2026-03-15T05:36:00.416025+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.